NeuroBo Pharmaceuticals, Inc. announced the appointment of current Board member, Hyung Heon ("H.H.") Kim, as the Company's Chief Executive Officer, effective immediately. Mr. Kim succeeds Joseph Hooker, who served as interim Chief Executive Officer and President since January 2023. Prior to his appointment as Chief Executive Officer and President, Mr. Kim served as the General Counsel and a Senior Vice President of Dong-A ST Co Ltd., currently the Company's largest stockholder and NeuroBo's partner with respect to its newly in-licensed assets, DA-1241 and DA-1726, potential therapies for nonalcoholic steatohepatitis (NASH), obesity and type 2 diabetes.

Mr. Kim has been with Dong-A and its affiliates in various roles since 2012.